mardi 26 février 2019

Onco Actu du 26 février 2019

2.6 ETIOLOGIE - ENVIRONNEMENT

Brazil health officials find weed-killer glyphosate non-cancerous [Reuters]

3.1 PRÉVENTION - TABAC

How big tobacco keeps cancer rates high in countries like mine [The Guardian]

4.10 DÉP., DIAG. & PRONO. - FDA, EMA, NICE,...

FDA issues warning letter to clinic illegally marketing unapproved thermography device, warns consumers to avoid using thermography devices to detect breast cancer [FDA]

4.12 BIOPSIES LIQUIDES

Breakthrough 'lab-on-a-chip' detects cancer faster, cheaper and less invasively [University of Kansas]

A New Sequencing Method To Detect DNA Modifications Of Relevance To Cancer [Ludwig Cancer Research]

5. TRAITEMENTS

Treatment for Children with Leukemia Also Effective for Adolescents, Young Adults [NCI]

Sperm Quality Unaffected by one Course of Chemotherapy for Early Testicular Cancer [Annals of Oncology Press Release]

5.10 TRAITEMENTS - ESSAIS

Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer [AstraZeneca]

AstraZeneca, Merck notch another major Lynparza trial win — this time in pancreatic cancer [End Points]

AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study [Reuters]

5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES

Autolus taps Vineti to help deliver personalized cell therapies [Fierce Biotech]

Cellectis Publishes Novel Methods to Improve the Safety of CAR T-Cell Therapy and Prevent CRS in the Journal of Biological Chemistry [Cellectis]

Temasek leads $85M round for Chinese biotech aiming for cheaper, faster, better CAR-T therapies [EndPoints]

5.2 PHARMA

Genmab Announces Positive Topline Results in Phase III COLUMBA Study of Subcutaneous Daratumumab [Genmab]

5.3 TRAITEMENTS - FDA, EMA, NICE...

Can Roche’s little tech startup help the FDA change clinical trials? [STAT]

5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)

FDA Approves Taiho Oncology’s LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma [Taiho]

5.4 TRAITEMENTS - ECONOMIE

Additional exclusivity for a cancer treatment could cost the public $3 billion, analyst says [EndPoints]

5.6 ESMO

Analysis Compares the Rates of Access of Adolescents and Young Adults to Clinical Trials of New Drugs [ESMO]

The Lung Immune Prognostic Index Significantly Associates with Outcome Across a Cancer Patient Population [ESMO]

Rare Cancers a Growing Focus of Early-stage Clinical Trials [ESMO]

6. LUTTE CONTRE LES CANCERS

Cancer services: how much is enough? [Cancer World]

6.10.1 POLITIQUES (USA)

How Pharma Lost Its Edge in Washington [Bloomberg]

6.4 MÉDICO-ÉCO

Impact investing: a new way to fund cures for cancer [STAT]